Exosomes News and Research

RSS

Researchers study molecular mechanisms in early stages of IPN virus infection

Infectious pancreatic necrosis is a serious disease that leads to enormous losses in the salmon industry each year. The virus that causes the disease, IPN, is very prevalent in farmed salmon and trout in Norway. The virus attacks a wide diversity of hosts and has been found to occur in many different fish species, in addition to shellfish and molluscs.

30 Dec 2010

Molecular-level insights into how physical activity influences the heart

Everyone knows that exercise comes with metabolic and cardiovascular benefits, but scientists understand surprisingly little about how physical activity influences the heart itself. Now, a new study in the December 23rd issue of Cell, a Cell Press publication, offers some of the first molecular-level insights.

24 Dec 2010

Chronic fatigue syndrome not linked to virus

The latest research from the University College London, the Wellcome Trust Sanger Institute, and University of Oxford, England suggests that chronic fatigue syndrome (CFS) is not caused by the virus XMRV (xenotropic murine leukemia virus-related virus). The team says that earlier research that linked the virus to CFS was faulty because of contamination of mouse cell DNA samples in the laboratory.

21 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Research: Stem cell culture on soft substrate maintain homogeneous pluripotent colonies

In a paper published in the journal PLoS One, the researchers demonstrated that culturing mouse embryonic stem cells on a soft gel rather than on a hard plate or dish keeps them in their pluripotent state, a ground state with the ability to become any type of tissue.

16 Dec 2010

New skincare product with cellular activators

Scientists in Iceland have developed a revolutionary skincare product after more than a decade of extensive research in plant biotechnology. The skin-rejuvenating phenomenon is called BIOEFFECT(TM) EGF Serum. Made by Sif Cosmetics, it is the world's first skincare product to contain cellular activators made in plants. Six months after its launch in Iceland, the serum is already being used by over 20% of Icelandic women.

15 Dec 2010

Cannabis Science signs lease for new corporate headquarters in Denver, Colorado

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce it has signed a lease for a new corporate headquarters as its new base of operations in Denver, Colorado. The 6,600 sq. ft. core facility at 2422 S. Trenton Way, Unit H will be dedicated to housing executive offices, administrative personnel, as well as the Lab Division core of operations for its cannabis formulations testing and FDA initiatives.

14 Dec 2010

Roche launches new xCELLigence System RTCA HT Instrument

The new xCELLigence System RTCA HT Instrument from Roche Diagnostics rounds out the company's portfolio in real-time cell analysis with a high-throughput product. The new instrument merges the power and flexibility of xCELLigence System technology with high-throughput analyses and workflows for automated screening applications.

From Roche Sequencing and Life Science 14 Dec 2010

EHSI negotiates potential option agreement with Regenetech for Rotary Cell Culture System

Emerging Healthcare Solutions, Inc. is negotiating a potential option agreement with biotech firm Regenetech, Inc.

14 Dec 2010

Scientists create functioning human intestinal tissue from pluripotent stem cells

For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells.

13 Dec 2010

Celulas Genetica to submit international patent application for Rutherford Procedure

Emerging Healthcare Solutions, Inc. announced today that its newly acquired biotechnology division Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease.

10 Dec 2010

EHSI announces acquisition of Rotary Cell Culture System

Emerging Healthcare Solutions, Inc. announced today that it has acquired a Rotary Cell Culture System, or bioreactor, developed using revolutionary NASA research in the field of microgravity.

4 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

Baxter licenses Vero cell-based influenza vaccine technology to Takeda

Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.

From Baxter International Inc. 2 Dec 2010

EHNA treatment blocks spontaneous differentiation of stem cells

Human embryonic stem cells have enormous potential for use in pharmaceutical development and therapeutics; however, to realize this potential there is a requirement for simple and reproducible cell culture methods that provide adequate numbers of cells of suitable quality.

26 Nov 2010

Diabetes drug may counteract against Alzheimer's disease: Research

Metformin, a drug used in type 2-diabetes might have the potential to also act against Alzheimer's disease. This has been shown in a study from scientists of the German Center for Neurodegenerative Diseases (DZNE), the University of Dundee and the Max-Planck-Institute for Molecular Genetics.

24 Nov 2010

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new data at the MIT Center for Biomedical Innovation's Biomanufacturing Summit from its platform efforts aimed at developing RNAi technologies for applications in biologics manufacturing.

19 Nov 2010

Researchers find clue behind dementia development

Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.

18 Nov 2010

Accentia and Biovest exit Chapter 11 as fully restructured organizations

Accentia Biopharmaceuticals, Inc. announced that, effective today, the Company and its majority-owned subsidiary, Biovest International, Inc., have both successfully completed their reorganizations. Pursuant to their respective Plans of Reorganization approved by the bankruptcy court, Accentia and Biovest have now formally exited Chapter 11 as fully restructured organizations.

18 Nov 2010